SecBot SecBot

ISCO

International Stem Cell CORP
OTC· Pharmaceutical Preparations· Inc. DE· CIK 0001355790 Biotech & Drug Discovery
$0.1500 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.1500
Next earnings
Nov 11
in 16 days
1 year
0.0%
from $0.1500 · Oct 27
30 days
−54.5%
from $0.3300
52-week range
$0.1200–0.5100
−71% from high · low Dec 29
Avg volume 20D
29.1K
Oct 21 spike 242.2K
Short interest
🔒 Subscribers only
Insider net
−$10.5K
0 buyers · 1 seller · 12 mo
Filing reports
3
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 11, 2026
Strongest MIXED International Stem Cell Corporation completed the sale of its wholly-owned subsidiary Lifeline Cell…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $10.5K.

  • TrendDOWNTREND

    56% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 16, 2026 Insider
MAIER PAUL V disposed of 30,000 shares
Director
Sep 11, 2026 SEC
Director Paul V. Maier filed a Form 144 notice of intent to sell 32,802 shares of International Stem Cell Corp (ISCO)…
144 — Impact 2/10
Sep 11, 2026 Insider
MAIER PAUL V sold 32,802 shares
Director @ $0.3200 ($10.5K)
Sep 8, 2026 SEC
International Stem Cell Corporation completed the sale of its wholly-owned subsidiary Lifeline Cell Technology (LCT)…
8-K — Impact 6/10
Aug 12, 2026 Earnings calendar
ISCO Q2 2026 Earnings Scheduled — 2026-08-12
Jul 15, 2026 SEC
International Stem Cell Corporation (ISCO) signed a definitive agreement to sell its wholly-owned subsidiary, Lifeline…
8-K — Impact 6/10
Jun 11, 2026 Insider
MAIER PAUL V was granted 30,000 shares
Director
Apr 22, 2026 Event
EPINEPHRINE Injection, USP, 1 mg/10mL (0.1 mg/mL), Rx only, INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So. EL Monte, CA 91733, An Amphastar Pharmaceutical Company, NDC 76329-3318-1
Class II: Lack of Assurance of Sterility

Insider ledger

Form 4
$0
bought · 0 insiders
$10.5K
sold · 1 insider
DateInsiderTypeValue
Sep 16, 2026
MAIER PAUL V
Director
TO ISSUER30,000 sh
Sep 11, 2026
MAIER PAUL V
Director
SELL$10.5K
Jun 11, 2026
MAIER PAUL V
Director
AWARD30,000 sh
Jun 11, 2026
Don Wright
Director
AWARD30,000 sh
Jun 11, 2026
Don Wright
Director
AWARD182,584 sh
Jun 11, 2026
MAIER PAUL V
Director
AWARD182,584 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
ISCO Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 12, 2026
Earnings date
ISCO Q2 2026 Earnings Scheduled — 2026-08-12
May 12, 2026
Earnings date
ISCO Q1 2026 Earnings Scheduled — 2026-05-12
Apr 22, 2026
FDA
EPINEPHRINE Injection, USP, 1 mg/10mL (0.1 mg/mL), Rx only, INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So. EL Monte, CA 91733, An Amphastar Pharmaceutical Company, NDC 76329-3318-1
Class II: Lack of Assurance of Sterility
Mar 26, 2026
Earnings date
ISCO Q4 2025 Earnings Scheduled — 2026-03-26

SecBot reports

3 filings · 1 bullish · 0 bearish · 1 mixed · 1 neutral
All ISCO filing & press-release reports (3)